Seaman et al. (2017) applied the anti-CD276 antibody to the ADC to improve the non-specificity. The CD276 expresses in angiogenic tumor vessel, existed vasculature and tumor cells. Moreover, the anti-CD276 antibody is capable of identifying the normal and pathological angiogenesis. The anti-CD276 ADC evaded the vessel co-option and displayed a dual-targeting ability thus displaying effective anti-tumor activity (Seaman et al., 2017). The gene discussed is CD276; the disease is neoplasm.